REGENXBIO Reports Q3 2026 Financial Results Amid Patent Expirations and Litigation Settlement
REGENXBIO (RGNX) reported third-quarter 2026 revenues of $9.2 million, a significant decrease from $29.7 million in the prior year due to patent expirations affecting ZOLGENSMA royalty income. Despite the revenue decline, the company narrowed its net loss to $40.7 million ($0.62 per share) compared to a $61.9 million loss in Q3 2025. The results were bolstered by a $38 million gain from a patent litigation settlement with Sarepta Therapeutics and a $100 million milestone payment from AbbVie. The company maintains a strong liquidity position with $251 million in cash and equivalents, supplemented by an additional $39 million received from the Sarepta settlement. Management expects this cash runway to extend into late 2027, supporting clinical milestones for the RGX-202 program. While R&D expenses rose to $61 million due to ongoing clinical trials, the company continues to advance its gene therapy pipeline, including large-scale enrollment for Sura-vec.